drugset / Trial / NCT01201798

Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

NCT01201798

Phase 3 Completed 111 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.

Timeline

Start
2010-10
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Difluprednate Small molecule 0.05 % Other
Comparator Prednisolone Other / unclassified 1 % Other

Indications